Post

Pharma industry groups push initiatives against climate change at COP28 

Several pharmaceutical industry advocacy and lobby organisations have bandied together to release a joint industry statement supporting the Declaration on …

Capmatinib hydrochloride by Novartis for Metastatic Melanoma: Likelihood of Approval

Capmatinib hydrochloride is under clinical development by Novartis and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase …

Cabiralizumab by Bristol-Myers Squibb for Melanoma: Likelihood of Approval

Cabiralizumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Melanoma. According to GlobalData, Phase I …

BMS-986360 by Bristol-Myers Squibb for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

BMS-986360 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to …

FPI-2059 by Fusion Pharmaceuticals for Metastatic Colorectal Cancer: Likelihood of Approval

FPI-2059 is under clinical development by Fusion Pharmaceuticals and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, …